| http://www.w3.org/ns/prov#value | - Rather, he says, the culprit is a troublesome combination of overly broad patents that are exclusively licensed to single companies.More than two-thirds of the patents examined in the case studies are held by universities or other nonprofit institutions that depend on government or nonprofits for much of their biomedical research funding, often including the research leading to gene patents.
|
